4D Molecular Therapeutics to present 2-year PRISM Phase 2b data for 4D-150 gene therapy in neovascular AMD at ASRS 2026

4D Molecular Therapeutics will present 2-year follow-up data from its PRISM Phase 2b trial of 4D-150 gene therapy for neovascular AMD at the ASRS 2026 meeting in Montreal. The July 18, 2026 podium update aims to inform expectations for 4D-150 as a longer-lasting treatment for wet age-related macular degeneration. 4D-150 is the company's lead Phase 3 program, with diabetic macular edema as a secondary target.

4D Molecular Therapeutics set a July 18, 2026 podium update on 2-year follow-up results from its PRISM Phase 2b trial of 4D-150. * The data will be presented in the future at the American Society of Retina Specialists annual meeting in Montreal. * The readout is positioned to inform expectations for 4D-150 as a longer-lasting treatment approach for wet age-related macular degeneration. * 4D-150 is the company’s lead program in Phase 3, with diabetic macular edema as a second target indication. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606301605PRIMZONEFULLFEED9754303) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

4D Molecular Therapeutics set a July 18, 2026 podium update on 2-year follow-up results from its PRISM Phase 2b trial of 4D-150. * The data will be presented in the future at the American Society of Retina Specialists annual meeting in Montreal. * The readout is positioned to inform expectations for 4D-150 as a longer-lasting treatment approach for wet age-related macular degeneration. * 4D-150 is the company’s lead program in Phase 3, with diabetic macular edema as a second target indication. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606301605PRIMZONEFULLFEED9754303) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)